Fluoguide Q3 2024: Gearing up for high-impact catalysts in 2025e - Redeye

Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s planned development in head and neck cancer. We judge the company faces various high-impact clinical and business development catalysts in 2025e. We adapt our estimates and valuation to the company’s recently announced plans. Our view of the investment case remains essentially unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/1061368/fluoguide-q3-2024-gearing-up-for-high-impact-catalysts-in-2025e?utm_source=finwire&utm_medium=RSS